Unaudited financial results for the quarter and nine months ended December 31, 2025, is submitted.
DRAGARWQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dr. Agarwal's Eye Hospital reported Q3 FY26 revenue of ₹116.22 Cr, up about 22% YoY from ₹95.11 Cr in Q3 FY25. Net profit after tax for the quarter rose sharply to ₹17.28 Cr from ₹10.40 Cr, a ~66% jump. For the nine months ended December 31, 2025, revenue grew ~18% YoY to ₹350.86 Cr, while PAT climbed ~39% to ₹53.86 Cr. EBITDA margins expanded to roughly 32% in Q3 and 33% for 9M FY26, up from around 29-31% a year ago, showing improved operating efficiency. The Board also approved shifting the registered office within Chennai and noted an ongoing amalgamation scheme with holding company Dr. Agarwal's Health Care Limited. A ₹70 Cr preferential issue to the holding company was completed in September 2025, and the statutory auditor changed to S.R. Batliboi & Associates LLP from the previous auditor who had reviewed prior periods.
Strong topline growth, a sharp jump in profits, and expanding margins signal healthy operational momentum, likely supportive of the stock. The amalgamation with the holding company and change of auditor are governance items shareholders should watch.